Expand AIM Menu
AIM MENU

AIM Latest Press Releases

-- April 16, 2026 --

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP Globe Newswire 9:00 AM

-- April 13, 2026 --

AIM ImmunoTech Provides Routine Update on Annual Filings Globe Newswire 6:00 PM

-- April 9, 2026 --

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event Globe Newswire 8:00 AM

-- March 18, 2026 --

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum Globe Newswire 10:41 AM
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors Globe Newswire 8:36 AM

-- March 6, 2026 --

AIM ImmunoTech Announces Closing of its Rights Offering Globe Newswire 7:00 PM

-- March 4, 2026 --

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million Globe Newswire 9:00 AM

-- March 2, 2026 --

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer Globe Newswire 9:00 AM

-- February 27, 2026 --

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering Globe Newswire 9:00 AM

-- February 25, 2026 --

AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 Globe Newswire 9:00 AM

-- February 23, 2026 --

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer Globe Newswire 8:55 AM

-- February 12, 2026 --

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering Globe Newswire 4:35 PM
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event Globe Newswire 8:55 AM

-- February 11, 2026 --

AIM ImmunoTech Announces Commencement of Rights Offering Globe Newswire 8:30 AM

-- February 9, 2026 --

JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026 ACCESS Newswire 11:30 AM

-- February 6, 2026 --

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial Globe Newswire 8:55 AM

-- February 5, 2026 --

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer Globe Newswire 8:40 AM

-- January 27, 2026 --

AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering Globe Newswire 4:35 PM

-- January 23, 2026 --

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering Globe Newswire 1:22 PM

-- December 30, 2025 --

AIM ImmunoTech Announces Stock Dividend Globe Newswire 5:10 PM

-- December 10, 2025 --

AIM ImmunoTech Announces Release of the Next CEO Corner Segment Globe Newswire 9:00 AM

-- December 1, 2025 --

AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series Globe Newswire 8:55 AM
Market Data Delayed 15 Minutes